Comparative efficacy of dapagliflozin and empagliflozin on hospitalization for heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction: a network meta-analysis
Abstract
Introduction: Heart Failure with Preserved Ejection Fraction (HFpEF) is a complex syndrome with increasing prevalence, especially among older populations with hypertension and diabetes. Despite similar mortality rates to heart failure with reduced ejection fraction (HFrEF), HFpEF remains difficult to manage due to limited effective treatments. Recent studies have highlighted the benefits of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, like dapagliflozin and empagliflozin, in improving outcomes in HFpEF. This meta-analysis aims to compare the efficacy of these two agents in reducing heart failure hospitalization and cardiovascular death.
Methods: This meta-analysis followed preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines. Relevant studies were identified through systematic searches in PubMed, Cochrane Library, and ScienceDirect using specific keywords. Eligible randomized controlled trials evaluating dapagliflozin and empagliflozin in HFpEF patients were included. Risk of bias was assessed using the Cochrane RoB2 Tool, and statistical analysis was conducted using a random effects model.
Results: Six phase III randomized controlled trials (RCTs) involving 36,478 participants (mean age ~71 years) were included. The studies, conducted across over 20 countries, compared empagliflozin and dapagliflozin to placebo in HFpEF patients. Empagliflozin showed the highest probability of reducing heart failure hospitalization (SUCRA 0.875)…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 36,478 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.